Acorda Therapeutics Stock Today

ACOR Stock  USD 13.21  1.30  10.92%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Over 63

 
100  
 
Zero
Quite High
Acorda Therapeutics is selling at 13.21 as of the 28th of March 2024; that is 10.92 percent increase since the beginning of the trading day. The stock's lowest day price was 11.82. Acorda Therapeutics has more than 63 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Acorda Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
10th of February 2006
Category
Healthcare
Classification
Health Care
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York. Acorda Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 1.24 M outstanding shares of which 9.46 K shares are presently shorted by private and institutional investors with about 5.15 trading days to cover. More on Acorda Therapeutics

Moving together with Acorda Stock

  0.75MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.7KA Kineta Inc Report 29th of March 2024 PairCorr

Moving against Acorda Stock

  0.86TCRX Tscan Therapeutics Financial Report 8th of May 2024 PairCorr
  0.74EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.67MESO Mesoblast TrendingPairCorr
  0.64DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.62MDWD Mediwound Downward RallyPairCorr
  0.61VANI Vivani Medical Report 29th of March 2024 PairCorr
  0.6MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Acorda Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Acorda Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Acorda Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEO, DirectorRon Cohen
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Acorda Therapeutics report their recommendations after researching Acorda Therapeutics' financial statements, talking to executives and customers, or listening in on Acorda Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Acorda Therapeutics. The Acorda consensus assessment is calculated by taking the average forecast from all of the analysts covering Acorda Therapeutics.
Financial Strength
Based on the key indicators related to Acorda Therapeutics' liquidity, profitability, solvency, and operating efficiency, Acorda Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Acorda Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.270.2997
Moderately Down
Slightly volatile
Gross Profit Margin0.70.67
Sufficiently Up
Slightly volatile
Total Current Liabilities83.3 M43.6 M
Way Up
Very volatile
Non Current Liabilities Total228.2 M303.6 M
Way Down
Slightly volatile
Total Assets586.8 M454.9 M
Significantly Up
Very volatile
Total Current Assets89.7 M94.4 M
Notably Down
Slightly volatile
Acorda Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Acorda Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Acorda Therapeutics' financial leverage. It provides some insight into what part of Acorda Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Acorda Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Acorda Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Acorda Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 172.92 M in liabilities with Debt to Equity (D/E) ratio of 2.56, implying the company greatly relies on financing operations through barrowing. Acorda Therapeutics has a current ratio of 1.68, which is within standard range for the sector. Debt can assist Acorda Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Acorda Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acorda Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acorda to invest in growth at high rates of return. When we think about Acorda Therapeutics' use of debt, we should always consider it together with cash and equity.

Capital Expenditures

92,150
Acorda Therapeutics (ACOR) is traded on NASDAQ Exchange in USA. It is located in 2 Blue Hill Plaza, Pearl River, NY, United States, 10965 and employs 111 people. Acorda Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acorda Therapeutics's market, we take the total number of its shares issued and multiply it by Acorda Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Acorda Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.24 M outstanding shares of which 9.46 K shares are presently shorted by private and institutional investors with about 5.15 trading days to cover. Acorda Therapeutics currently holds about 20.7 M in cash with (1.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85.
Check Acorda Therapeutics Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Acorda Therapeutics is currently $15.4 Million. Almost 86.0 percent of Acorda Therapeutics outstanding shares are held by general public with 0.689 (percent) owned by insiders and only 13.22 % by other corporate entities. Be advised that no matter how volatile the entity is, if the real value of the firm is more than the value suggested by the market, you should consider buying it.
Check Acorda Ownership Details

Acorda Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of Acorda Therapeutics jumping above the current price in 90 days from now is about 82.14%. The Acorda Therapeutics probability density function shows the probability of Acorda Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Acorda Therapeutics has a beta of 0.7119. This suggests as returns on the market go up, Acorda Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Acorda Therapeutics will be expected to be much smaller as well. Additionally, acorda Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 13.21HorizonTargetOdds Above 13.21
17.77%90 days
 13.21 
82.14%
Based on a normal probability distribution, the odds of Acorda Therapeutics to move above the current price in 90 days from now is about 82.14 (This Acorda Therapeutics probability density function shows the probability of Acorda Stock to fall within a particular range of prices over 90 days) .

Acorda Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Acorda Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acorda Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acorda Therapeutics' value.
InstituionRecorded OnShares
Jpmorgan Chase & Co2023-09-30
2.0
Advisor Group Holdings, Inc.2023-09-30
2.0
Qube Research & Technologies2023-09-30
1.0
Royal Bank Of Canada2023-09-30
0.0
Fmr Inc2023-09-30
0.0
Group One Trading, Lp2023-09-30
0.0
Davidson Kempner Capital Management Lp2023-09-30
55.1 K
Renaissance Technologies Corp2023-12-31
45.8 K
Acadian Asset Management Llc2023-09-30
33.7 K
Vanguard Group Inc2023-09-30
10.7 K
Blackrock Inc2023-12-31
6.6 K
View Acorda Therapeutics Diagnostics

Acorda Therapeutics Historical Income Statement

Acorda Therapeutics Income Statement is one of the three primary financial statements used for reporting Acorda's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Acorda Therapeutics revenue and expense. Acorda Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Acorda Therapeutics' Extraordinary Items is relatively stable compared to the past year. As of 03/28/2024, Non Operating Income Net Other is likely to grow to about 67.7 M, while Total Revenue is likely to drop slightly above 105.6 M. View More Fundamentals

Acorda Stock Against Markets

Picking the right benchmark for Acorda Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Acorda Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Acorda Therapeutics is critical whether you are bullish or bearish towards Acorda Therapeutics at a given time. Please also check how Acorda Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Acorda Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Acorda Therapeutics Corporate Directors

Acorda Therapeutics corporate directors refer to members of an Acorda Therapeutics board of directors. The board of directors generally takes responsibility for the Acorda Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Acorda Therapeutics' board members must vote for the resolution. The Acorda Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Lorin RandallIndependent DirectorProfile
John KelleyIndependent DirectorProfile
Peder JensenIndependent DirectorProfile
Ian SmithIndependent DirectorProfile

How to buy Acorda Stock?

Before investing in Acorda Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Acorda Therapeutics. To buy Acorda Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Acorda Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Acorda Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Acorda Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Acorda Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Acorda Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Acorda Stock please use our How to Invest in Acorda Therapeutics guide.

Already Invested in Acorda Therapeutics?

The danger of trading Acorda Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acorda Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acorda Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acorda Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Acorda Therapeutics is a strong investment it is important to analyze Acorda Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Acorda Therapeutics' future performance. For an informed investment choice regarding Acorda Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acorda Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in Acorda Stock, please use our How to Invest in Acorda Therapeutics guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Acorda Stock analysis

When running Acorda Therapeutics' price analysis, check to measure Acorda Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acorda Therapeutics is operating at the current time. Most of Acorda Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acorda Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acorda Therapeutics' price. Additionally, you may evaluate how the addition of Acorda Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Bonds Directory
Find actively traded corporate debentures issued by US companies
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Transaction History
View history of all your transactions and understand their impact on performance
Is Acorda Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acorda Therapeutics. If investors know Acorda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acorda Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.873
Earnings Share
2.61
Revenue Per Share
87.938
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.03)
The market value of Acorda Therapeutics is measured differently than its book value, which is the value of Acorda that is recorded on the company's balance sheet. Investors also form their own opinion of Acorda Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acorda Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acorda Therapeutics' market value can be influenced by many factors that don't directly affect Acorda Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acorda Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acorda Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acorda Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.